

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

**IN RE: OZEMPIC (SEMAGLUTIDE)
PATENT LITIGATION**

No. 22-md-3038-CFC

**NOVO NORDISK INC. and NOVO
NORDISK A/S,**

No. 22-cv-294-CFC
CONSOLIDATED
ANDA CASE

Plaintiffs/Counterclaim
Defendants,

v.

RIO BIOPHARMACEUTICALS INC. et al.,

Defendants/Counterclaim
Plaintiffs.

**NOVO NORDISK INC. and NOVO
NORDISK A/S,**

No. 22-cv-1040-CFC
ANDA CASE

Plaintiffs/Counterclaim
Defendants,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant/Counterclaim
Plaintiff.

**Opening Expert Report of Dr. John Bantle
Regarding Invalidity of U.S. Patent No. 10,335,462**

TABLE OF CONTENTS

| | Page |
|--|------|
| I. Qualifications and Background..... | 1 |
| A. Education and Experience; Prior Testimony | 1 |
| B. Basis for Opinions and Materials Considered | 4 |
| C. Retention and Compensation | 4 |
| II. Summary of Opinions | 4 |
| III. Legal Standards | 7 |
| IV. Person of Ordinary Skill in the Art..... | 9 |
| V. The '462 Patent and Its Asserted Claims | 11 |
| VI. Claim Construction..... | 19 |
| VII. Background on Diabetes and the use of GLP-1 Derivatives for the Treatment of Diabetes..... | 20 |
| A. Diabetes Generally | 20 |
| B. Diabetes Treatment..... | 22 |
| C. The Use of GLP-1 Derivatives to Treat Diabetes..... | 25 |
| D. Use of Liraglutide to Treat Diabetes | 27 |
| E. Extended-Use GLP-1 Receptor Agonists | 32 |
| VIII. Scope and Content of the Prior Art | 41 |
| A. Lovshin..... | 43 |
| B. Madsbad | 45 |
| C. U.S. Patent No. 8,114,833..... | 47 |
| D. WO 2006/097537..... | 54 |
| E. WO 2011/138421 | 60 |
| F. NCT00696657 Semaglutide Clinical Trial Record | 64 |
| 1. Clinical Trial No. NCT00696657 | 64 |
| 2. ClinicalTrials.gov is a Part of the POSA's Knowledge..... | 66 |
| G. Other Technical Background Forming the POSA's Knowledge | 73 |

TABLE OF CONTENTS
(continued)

| | Page |
|---|-------------|
| 1. Clinical Trial No. NCT00851773 | 73 |
| 2. Bhansali | 79 |
| 3. Drucker 2003..... | 84 |
| 4. Holst 2004..... | 85 |
| 5. Knudsen 2001 | 89 |
| 6. Knudsen 2004 | 93 |
| 7. Knudsen patent (U.S. Patent No. 6,268,343)..... | 98 |
| 8. Lund..... | 103 |
| 9. U.S. Patent Application Pub. No. US2007/0010424 | 103 |
| 10. Victoza label..... | 108 |
| 11. WO 03/002136 | 111 |
| 12. Additional prior art and references | 116 |
| IX. Invalidity of the Asserted Claims of the '462 Patent..... | 117 |
| A. Each of WO '421, NCT00696657, and Lovshin anticipated claims 1 and 3..... | 117 |
| 1. WO '421 | 118 |
| 2. NCT00696657..... | 126 |
| 3. Lovshin..... | 133 |
| B. All Asserted Claims of the '462 Patent Would Have Been Obvious Over the Prior Art | 141 |
| 1. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '421, NCT00696657, WO '537 and/or Lovshin, optionally in view of one or more of the '833 Patent and Madsbad | 142 |
| 2. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '421 alone or in view of the '833 patent | 168 |
| 3. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '537 in view of Lovshin | 181 |

TABLE OF CONTENTS
(continued)

| | Page |
|---|-------------|
| C. All Claims of the '462 Patent Are Invalid for Lack of Written Description if They Would not have been Obvious | 194 |
| X. Reservation of Rights | 202 |

TABLE OF ABBREVIATIONS

| Full Name of Cited Reference | Abbreviation |
|--|-------------------------------|
| U.S. Patent Application Pub. No. US2011/0166321 | '321 publication |
| U.S. Patent Application Pub. No. US2007/0010424 | '424 publication |
| U.S. Patent No. 10,335,462 NN-OZEM-000000071-95 | '462 patent |
| U.S. Patent No. 10,335,462 file history NN-OZEM-000003820-4446 | '462 file history |
| U.S. Patent No. 5,512,549 | '549 patent |
| U.S. Patent No. 8,114,833 SEMA(JDG)_0000447-468 | '833 patent |
| Banting, <i>The Internal Secretion of the Pancreas</i> , 7 J. LAB. CLINICAL MED. 251 (1922) | Banting |
| Bell, <i>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides</i> , 302 NATURE 716 (1983) | Bell |
| Bhansali, <i>Historical Overview of Incretin Based Therapies</i> , 58 J. ASSOC. OF PHYSICIANS OF INDIA 10 (2010) SEMA(JDG)_0000014-18 | Bhansali |
| Highlights of Prescribing Information: Bydureon, Rev. 1/2012 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200Orig1s0001bledt.pdf (last accessed Feb. 26, 2024) | Bydureon label |
| Highlights of Prescribing Information: Byetta, Rev. 10/2009 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25l1.pdf (last accessed Feb. 26, 2024) | Byetta label |
| <i>ClinicalTrials.gov Background</i> , CLINICALTRIALS.GOV, https://clinicaltrials.gov/about-site/about-ctg (last visited Mar. 15, 2024) | ClinicalTrials.gov Background |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.